Follow Alkermes, Inc.. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.
11 Stories in coverage 53 approved Programs 108 recruiting Registered trials 8-K Nov 12 Latest SEC filing Nov 12 Latest story
Timeline 11 Pipeline 5 Trials 10
All11 Trials and readouts4 Filings and people7
Pipeline by stage
Approved 3 Other 2
Phase 3 primary completions, next 6 months
All trials by completion date Details
Headquarters Dublin 4, L2 Industry Pharmaceutical Preparations Formerly ANTLER SCIENCE TWO PLC (to 2011); Antler Science Two Ltd (to 2011) Also known as Alkermes plc., ALKS, Antler Science Two Ltd, ANTLER SCIENCE TWO PLC How the company describes itself Alkermes develops neuroscience medicines including commercial products for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and narcolepsy. The company has late-stage clinical candidates for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early development for ADHD and fatigue in multiple sclerosis and Parkinson's disease. Headquartered in Ireland with operations in Massachusetts and Ohio. source